Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A. Girgis RR, et al. Among authors: laszlovszky i. Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12. doi: 10.1007/s00213-016-4382-y. Epub 2016 Aug 15. Psychopharmacology (Berl). 2016. PMID: 27525990 Free PMC article.
Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.
Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Nemeth G, Migliore R, Volk S. Durgam S, et al. Among authors: laszlovszky i. Psychopharmacology (Berl). 2017 Jan;234(2):199-209. doi: 10.1007/s00213-016-4450-3. Epub 2016 Nov 2. Psychopharmacology (Berl). 2017. PMID: 27807604 Free PMC article. Clinical Trial.
Cariprazine in the treatment of schizophrenia: a proof-of-concept trial.
Durgam S, Litman RE, Papadakis K, Li D, Németh G, Laszlovszky I. Durgam S, et al. Among authors: laszlovszky i. Int Clin Psychopharmacol. 2016 Mar;31(2):61-8. doi: 10.1097/YIC.0000000000000110. Int Clin Psychopharmacol. 2016. PMID: 26655732 Free PMC article. Clinical Trial.
Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Agai-Csongor E, Domány G, Tihanyi K, Adham N, Szombathelyi Z. Kiss B, et al. Among authors: laszlovszky i. J Pharmacol Exp Ther. 2010 Apr;333(1):328-40. doi: 10.1124/jpet.109.160432. Epub 2010 Jan 21. J Pharmacol Exp Ther. 2010. PMID: 20093397
Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.
Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horváth A, Pásztor G, Kapás M, Gyertyán I, Farkas S, Innis RB, Halldin C, Gulyás B. Seneca N, et al. Among authors: laszlovszky i. Psychopharmacology (Berl). 2011 Dec;218(3):579-87. doi: 10.1007/s00213-011-2343-z. Epub 2011 May 28. Psychopharmacology (Berl). 2011. PMID: 21625907 Free PMC article.
Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors.
Agai-Csongor E, Domány G, Nógrádi K, Galambos J, Vágó I, Keserű GM, Greiner I, Laszlovszky I, Gere A, Schmidt E, Kiss B, Vastag M, Tihanyi K, Sághy K, Laszy J, Gyertyán I, Zájer-Balázs M, Gémesi L, Kapás M, Szombathelyi Z. Agai-Csongor E, et al. Among authors: laszlovszky i. Bioorg Med Chem Lett. 2012 May 15;22(10):3437-40. doi: 10.1016/j.bmcl.2012.03.104. Epub 2012 Apr 4. Bioorg Med Chem Lett. 2012. PMID: 22537450
58 results